摘要
Abstract
Objective To investigate the pancreatic islet cell isolation technology,quality standards,and allograft islet cell transplantation in the treatment of type 1 diabetes safety and effectiveness. Methods According to Juvenile Diabetes Research Foundation (JDRF) standard screening method,three cases of type 1 diabetes (T1DM) were selected as allograft islet cells recipi-ents. Using Liberase enzyme digested pancreatic organs,COBE 2991 cell separator,and discontinuous density gradient purification-to obtained high purity and high activity of islet cells. All these procedures were conducted in our GMP facilities. Cultured after 12h,testing islets reached transplant standards,then performed percutaneous hepatic portal vein trunk of the recipients,islet cells were through the portal vein into the recipient liver site. After islet transplantation,using a modified Edmonton immunosuppressive protocol controlled rejection,and monitored of blood glucose,C peptide and glycate hemoglobin level changes regularly for 1-year followed-up. Results 2 cases completely out of insulin therapy,1 case compared with the preoperative insulin dosage reduction of 60% or more. Postoperative blood glucose was stable,C peptide and glycosylated hemoglobin were in the normal range,as well as improved renal function. No transplant complications and hypoglycemia were observed. Conclusion Allograft islet cell transplan-tation and the improved Edmonton scheme in the short-term for treatment of type 1 diabetes is safety and effectiveness.关键词
胰岛细胞/同种异体移植/糖尿病/护理Key words
pancreatic islet cells/allograft transplantation/diabetes mellitus分类
医药卫生
